Last reviewed · How we verify
Treatment of Pulmonary Disease Caused by MAIS, M.Xenopi or M.Malmoense: A Comparison of Two Triple Drug Regimens and an Assessment of the Value of Immunotherapy With M.Vaccae
To date key drugs in the treatment of MAIS, M.malmoense and M.xenopi (Opportunist Mycobacteria have been rifampicin and ethambutol. Clarithromycin and Ciprofloxacin are active in vitro against these species of mycobacteria. The primary aim of this study was to compare these to agents as supplements to rifampicin and ethambutol. A secondary aim was to assess the vale of immunotherapy with M.vaccae.
Details
| Lead sponsor | British Thoracic Society |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 400 |
| Start date | 1995-03 |
| Completion | 2004-09 |
Conditions
- Pulmonary Diseases
Interventions
- Addition of clarithromycin to rifampicin and ethambutol
- Addition of Ciprofloxacin to rifampicin and ethambutol
- Vaccination with M.vaccae
Primary outcomes
- Death rates
- Cure rates
- Relapse rates
- Unwanted effects of therapy
Countries
United Kingdom